RE:RE:EY sees bolt-ons in the single to double digit billions now Should read: - ONCY is demonstrating that the sequential administration of intravenous (IV) pelareorep with immune checkpoint inhibitors in patients who have been identified with predicitve/prognostic biomarkers that find changes in blood T cell populations (CeLTiLs/T-cell clonality) to predict patient response is proving to be a significantly effective.
This approach has proven more effective than other OVs which, in contrast, have been administered simultaneously with immune checkpoint inhibitors, such as Amgen's Imlygic that was given together with Merck's Keytruda. This Imlygic/Keytruda combination trialed relapsed/refractory melanoma failed because the virus was administered intratumorally (IT) with Keytruda in a broad population of melanoma patients, who were not previously identified by any biomarker for patient response to this therapy and who had peviously failed 2-3 courses of PD-1 therapy before they were included in this IT OV / IV ICI combo trial. Unfortunately, the Amgen/Merck OV/ICI study design was flawed from the start.